3Billion Inc is a Korea-based company principally engaged in the provision of genetic testing services. The Company is principally engaged in the provision of rare genetic disease diagnostic testing services. The Company is also engaged in the research and development of technology that automatically reads the pathogenicity of numerous genetic variants found in the genome.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-10-30	₩5,350.00	-13.01%	595,565
26-10-29	₩6,150.00	-0.81%	747,448
26-10-28	₩6,200.00	+11.11%	1,110,266
26-10-27	₩5,580.00	-1.24%	799,118
26-10-26	₩5,650.00	+13.00%	1,508,290

End-of-day quote Korea S.E.

More quotes

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - 3billion, Inc.

Company calendar

End-of-day quote Korea S.E. 2026-10-30			5-day change	1st Jan Change
5,350.00 ^KRW	-13.01%		+7.00%	-70.65%

Jun. 01	3billion Launches 3B-NEO, Genomic Newborn Screening Service Covering 595 Clinically Actionable Genetic Conditions	CI
May. 12	3billion, Inc. announced that it has received KRW 29.9999999 billion in funding from Meritz Securities Co., Ltd., Wonik Investment Partners Co., Ltd.	CI

Market Cap	170B 128M 114M 105M 95.28M 178M 12.12B 181M 1.25B 503M 6.38B 479M 469M 20.11B	P/E 2025	-107x	P/E 2026 *	-
Enterprise Value	153M 115K 103K 94.72K 85.82K 160K 10.92M 163K 1.13M 453K 5.74M 431K 422K 18.11M	EV / Sales 2025	49x	EV / Sales 2026 *	10.6x
Free-Float	75.33%	Yield 2025 *	-	Yield 2026 *	-

Jun. 01	3billion Launches 3B-NEO, Genomic Newborn Screening Service Covering 595 Clinically Actionable Genetic Conditions	CI
May. 12	3billion, Inc. announced that it has received KRW 29.9999999 billion in funding from Meritz Securities Co., Ltd., Wonik Investment Partners Co., Ltd.	CI
Apr. 22	3billion, Inc. announced that it expects to receive KRW 29.999999888 billion in funding from Meritz Securities Co., Ltd., Wonik Investment Partners Co., Ltd. and other investors.	CI
Apr. 09	3Billion Inc wins 955 million won order	RE
Mar. 22	3billion, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
25-03-18	3Billion Inc Wins 655 Million Won Order	RE

1 day	-13.01%
1 week	+7.00%
1 month	-16.93%
3 months	+4.09%
6 months	-60.40%
Current year	-70.65%

3billion, Inc. Stock

Stocks

A394800

KR7394800007

Biotechnology & Medical Research

Valuation: 3billion, Inc.

Chart: 3billion, Inc.

Latest news: 3billion, Inc.

Quotes and Performance

Price Extremes

Managers and Directors: 3billion, Inc.

Latest insider transactions

Bio Diagnostics & Testing

Financials

Company Profile

Quotes

Annual profits - Rate of surprise

1 week	4,990	6,300
1 month	4,870	6,440
Current year	4,020	18,690
1 year	4,020	20,100
3 years	3,025	20,100
5 years	3,025	20,100
10 years	3,025	20,100

Manager	Title	Age	Since
Chang-Won Geum CEO	Chief Executive Officer	45	2016-10-09
Soon-Il Park DFI	Director of Finance/CFO	46	2020-09-30
Jeong-Seol Lee CTO	Chief Tech/Sci/R&D Officer	46	2018-07-31

Director	Title	Age	Since
Chang-Won Geum BRD	Director/Board Member	45	2016-10-09
Se-Hwan Kim BRD	Director/Board Member	44	2016-10-09
Ki-Hyeon Kang BRD	Director/Board Member	44	2020-11-17

Date	Insider	Type	Main position	Quantity	% Market Cap.
4/16/25	Soon-Il Park	Others	Chief Financial Officer	44,000	0.1387%
3/7/25	Soon-Il Park	Exercice	Chief Financial Officer	40,000	0.1262%
3/7/25	Ki-hyun Kang	Exercice		10,000	0.0316%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
3BILLION, INC.	-13.01%	+7.00%	-41.91%	-	128M
WUXI APPTEC CO., LTD.	-0.62%	-1.87%	+42.87%	+64.15%	63.77B
ARGENX SE	+0.35%	+3.20%	+14.40%	+81.76%	56.37B
LONZA GROUP AG	+0.53%	+1.96%	+16.24%	+103.35%	54.62B
IQVIA HOLDINGS INC.	-2.81%	-4.31%	+23.50%	+47.83%	44.06B
BEONE MEDICINES AG	-0.33%	-1.93%	+19.28%	+98.80%	42.11B
REVOLUTION MEDICINES, INC.	+0.55%	+2.31%	+225.14%	+866.21%	41B
GENMAB A/S	+3.27%	+47.96%	+112.84%	+96.58%	34.92B
CELLTRION, INC.	+1.22%	-1.44%	+14.57%	+46.95%	32.82B
INSMED INCORPORATED	+0.89%	+20.55%	-40.62%	+349.24%	24.7B
Average	-1.00%	+6.25%	+38.63%	+194.99%	39.45B
Weighted average by Cap.	+0.17%	+5.44%	+47.96%	+176.67%

	2025	2026 *
Net sales	10.8B 8.1M 7.25M 6.67M 6.04M 11.3M 769M 11.51M 79.55M 31.93M 404M 30.39M 29.74M 1.28B	16B 12M 10.74M 9.88M 8.95M 16.74M 1.14B 17.05M 118M 47.31M 599M 45.02M 44.06M 1.89B
Net income	-5.8B -4.35M -3.89M -3.58M -3.25M -6.07M -413M -6.18M -42.72M -17.15M -217M -16.32M -15.97M -685M	-
Net Debt	-16.9B -12.67M -11.35M -10.44M -9.46M -17.68M -1.2B -18.01M -124M -49.97M -633M -47.55M -46.54M -2B	-